Lumos Diagnostics Holdings Ltd Asset Resilience Ratio
Lumos Diagnostics Holdings Ltd asset resilience ratio. Lumos Diagnostics Holdings Ltd (LDX) has an Asset Resilience Ratio of 14.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LDX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lumos Diagnostics Holdings Ltd (2017–2024)
Asset resilience ratio of Lumos Diagnostics Holdings Ltd from 2017 to 2024. This chart shows how Lumos Diagnostics Holdings Ltd's Asset Resilience Ratio has changed over time. See LDX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Lumos Diagnostics Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LDX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.99 Million | 14.18% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.99 Million | 14.18% |
Asset Resilience Insights
- Moderate Liquidity: Lumos Diagnostics Holdings Ltd has 14.18% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Lumos Diagnostics Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Lumos Diagnostics Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
Lumos Diagnostics Holdings Ltd Asset Resilience Ratio by Year (2017–2024)
Lumos Diagnostics Holdings Ltd asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for Lumos Diagnostics Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.40% | AU$1.96 Million ≈ $1.38 Million |
AU$20.81 Million ≈ $14.73 Million |
-14.74pp |
| 2023-12-31 | 24.14% | AU$6.48 Million ≈ $4.58 Million |
AU$26.84 Million ≈ $18.99 Million |
+12.28pp |
| 2022-12-31 | 11.86% | AU$3.02 Million ≈ $2.13 Million |
AU$25.42 Million ≈ $17.99 Million |
-9.74pp |
| 2021-12-31 | 21.60% | AU$7.98 Million ≈ $5.64 Million |
AU$36.94 Million ≈ $26.14 Million |
-24.21pp |
| 2020-12-31 | 45.81% | AU$44.89 Million ≈ $31.76 Million |
AU$97.99 Million ≈ $69.33 Million |
+43.00pp |
| 2019-12-31 | 2.81% | AU$850.30K ≈ $601.64K |
AU$30.28 Million ≈ $21.42 Million |
-9.05pp |
| 2018-12-31 | 11.86% | AU$3.01 Million ≈ $2.13 Million |
AU$25.40 Million ≈ $17.97 Million |
+9.31pp |
| 2017-12-31 | 2.55% | AU$226.43K ≈ $160.21K |
AU$8.89 Million ≈ $6.29 Million |
-- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more